VTRS.NASDAQViatris INC

Form 4: Viatris Inc. Executive Le Goff Reports Stock Transactions Following RSU Vesting

Sentiment:

SEC Form 4


Chief Commercial Officer Corinne Le Goff reports the vesting and settlement of restricted stock units (RSUs) and associated dividend equivalent units (DEUs) resulting in the acquisition and disposal of Viatris Inc. common stock.

Summary

  • On April 15, 2025, Corinne Le Goff, Chief Commercial Officer of Viatris Inc., reported transactions related to the vesting and settlement of restricted stock units (RSUs) and dividend equivalent units (DEUs).
  • A total of 39,344 RSUs granted on April 18, 2024, vested on April 15, 2025, resulting in the acquisition of 39,344 shares of common stock.
  • Concurrently, 1,768 dividend equivalent units (DEUs) were settled, also resulting in the acquisition of common stock.
  • To cover tax liabilities associated with the vesting and settlement, 19,023 shares were withheld at a price of $7.48 per share for the RSUs and 855 shares were withheld at the same price for the DEUs.
  • Following these transactions, Le Goff directly owns 42,331 shares of Viatris Inc. common stock and 39,344 RSUs that will vest on April 15, 2026, as well as 1,768 DEUs.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about executive compensation and ownership.

Future Outlook

The document indicates that 39,344 RSUs will vest on April 15, 2026.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock. It reflects part of the executive compensation structure common in publicly traded companies, using stock-based compensation to align management's interests with those of shareholders.

Comparison to Industry Standards

  • Stock-based compensation, including RSUs and DEUs, is a common practice among publicly traded pharmaceutical companies like Viatris, Teva, and Novartis.
  • The vesting schedules and tax withholding practices described in the document are standard procedures for RSU grants.
  • Comparing the size of the RSU grants and the resulting share ownership to those of executives at peer companies would provide a more comprehensive assessment of Le Goff's compensation package relative to industry norms.

Stakeholder Impact

  • The transactions have a minor impact on shareholders as they reflect the standard execution of executive compensation plans.
  • Employees may be interested in the details of executive compensation as it relates to overall company performance and equity distribution.

Key Dates

DateDescription
04/18/2024Date of grant for the restricted stock units (RSUs).
04/15/2025Date of transaction: vesting and settlement of RSUs and DEUs, and withholding of shares for tax liabilities.
04/15/2026Date when the remaining 39,344 RSUs will vest.

Keywords

Viatris Inc, Corinne Le Goff, RSU, DEU, Stock Options, Form 4, Beneficial Ownership, Executive Compensation

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.